All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the European Hematology Association (EHA) 2023 Congress, the Lymphoma Hub spoke to Chan Cheah, Sir Charles Gairdner Hospital, Perth, AU. We asked, What are the treatment options for patients with MCL who relapse after BTKi therapy?
What are the treatment options for patients with MCL who relapse after BTKi therapy?
Outcomes for patients with mantle cell lymphoma (MCL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) can be poor, with a median overall survival of 6–12 months. Here, Cheah discusses the benefits and drawbacks of different agents considered for patients with BTKi relapsed/refractory MCL, including chimeric antigen receptor T-cell therapies, non-covalent BTKis, and bi-specific antibodies. Not all these therapies are globally available; therefore, he discusses the importance of enrolling patients with MCL for clinical trials to help develop new treatments.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Efficacy and safety of brexucabtagene autoleucel in patients with R/R MCL: a real-world analysis
The Lymphoma Hub is pleased to present a visual abstract summarizing key safety and efficacy outcomes from a retrospective study of brexucabtagene...
Novel combinations for R/R MCL: Key updates from ASH 2022
The article predominantly focuses on results presented at ASH 2022 from interventional studies of novel combination therapies in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox